X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (224) 224
radioimmunotherapy (188) 188
oncology (182) 182
non-hodgkins-lymphoma (146) 146
i-131 tositumomab (131) 131
iodine i-131 tositumomab (130) 130
antibodies, monoclonal - therapeutic use (124) 124
refractory low-grade (120) 120
b-cell lymphoma (107) 107
rituximab (102) 102
ibritumomab tiuxetan radioimmunotherapy (101) 101
follicular lymphoma (94) 94
index medicus (91) 91
radioimmunotherapy - methods (88) 88
hematology (86) 86
therapy (80) 80
low-grade (77) 77
radiology, nuclear medicine & medical imaging (74) 74
chemotherapy (68) 68
anti-cd20 monoclonal-antibody (65) 65
treatment outcome (65) 65
phase-ii trial (63) 63
female (62) 62
male (58) 58
middle aged (57) 57
antineoplastic agents - therapeutic use (56) 56
lymphoma, non-hodgkin - radiotherapy (56) 56
adult (51) 51
aged (51) 51
lymphoma (48) 48
cancer (46) 46
immunotherapy (46) 46
follow-up (44) 44
animals (42) 42
non-hodgkin's lymphoma (41) 41
antibodies, monoclonal - adverse effects (38) 38
chronic lymphocytic-leukemia (38) 38
ibritumomab tiuxetan (38) 38
term-follow-up (38) 38
stem-cell transplantation (36) 36
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
lymphomas (35) 35
combined modality therapy (34) 34
lymphoma, b-cell - radiotherapy (34) 34
monoclonal antibodies (34) 34
radiotherapy (34) 34
antibodies, monoclonal - administration & dosage (33) 33
antigens, cd20 - immunology (33) 33
disease-free survival (33) 33
y-90 ibritumomab tiuxetan (32) 32
antibodies, monoclonal, murine-derived (30) 30
clinical trials as topic (30) 30
monoclonal-antibody (30) 30
aged, 80 and over (29) 29
lymphoma, non-hodgkin - drug therapy (29) 29
non-hodgkin's lymphomas (29) 29
yttrium radioisotopes - therapeutic use (29) 29
fractionated radioimmunotherapy (28) 28
phase i/ii trial (28) 28
care and treatment (27) 27
iodine radioisotopes - therapeutic use (27) 27
lymphoma, non-hodgkin - therapy (27) 27
phase-ii (27) 27
trial (27) 27
antibody (26) 26
high-dose therapy (26) 26
radioimmunotherapy - adverse effects (26) 26
y-90-ibritumomab tiuxetan (25) 25
transplantation (24) 24
i-131 (23) 23
lymphoma, non-hodgkin - immunology (23) 23
medicine, research & experimental (23) 23
mice (23) 23
cd20 (22) 22
immunology (22) 22
pharmacology & pharmacy (22) 22
tositumomab (22) 22
lymphoma, follicular - radiotherapy (21) 21
monoclonal antibody (21) 21
multicenter phase-ii (21) 21
progression-free survival (21) 21
anti-cd20 antibody (20) 20
bone-marrow-transplantation (20) 20
dosimetry (20) 20
non-hodgkin lymphoma (20) 20
tositumomab/iodine i-131 tositumomab (20) 20
idec-y2b8 radioimmunotherapy (19) 19
radiopharmaceuticals - therapeutic use (19) 19
acute myeloid-leukemia (18) 18
hematology, oncology and palliative medicine (18) 18
lymphoma, follicular - pathology (18) 18
lymphoma, non-hodgkin - pathology (18) 18
article (17) 17
immunoconjugates - therapeutic use (17) 17
lymphoma, follicular - drug therapy (17) 17
radiotherapy dosage (17) 17
time factors (17) 17
antibodies, monoclonal, humanized (16) 16
chop chemotherapy (16) 16
group protocol s9911 (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 01/2013, Volume 31, Issue 3, pp. 314 - 320
Journal Article
Cancer, ISSN 0008-543X, 02/2006, Volume 106, Issue 3, pp. 616 - 622
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 12/2013, Volume 19, Issue 23, pp. 6624 - 6632
There is currently no consensus on optimal frontline therapy for patients with follicular lymphoma. We analyzed a phase III randomized intergroup trial... 
STAGING SYSTEM | SURVIVAL | LOW-GRADE LYMPHOMA | TOSITUMOMAB/IODINE I-131 TOSITUMOMAB | SOUTHWEST-ONCOLOGY-GROUP | GROUP PROTOCOL S9911 | ONCOLOGY | SERUM BETA-2-MICROGLOBULIN | NON-HODGKIN-LYMPHOMA | FOLLOW-UP | CHEMOTHERAPY
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 1, pp. 123 - 128
Abstract The purpose of this study was to evaluate the standard outpatient dose of 131-Iodine tositumomab (75 cGy) combined with high-dose carmustine,... 
Hematology, Oncology and Palliative Medicine | 131-Iodine tositumomab | Diffuse large B cell lymphoma | Autologous stem cell transplantation | Radioimmunotherapy | TOTAL-BODY IRRADIATION | I/II TRIAL | PLUS RITUXIMAB | CHOP CHEMOTHERAPY | IMMUNOLOGY | CONDITIONING REGIMEN | TRANSPLANTATION | REFRACTORY LOW-GRADE | NON-HODGKINS-LYMPHOMA | IODINE I-131 TOSITUMOMAB | HEMATOLOGY | ANTIBODY THERAPY | IBRITUMOMAB TIUXETAN ZEVALIN | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Antineoplastic Agents - administration & dosage | Cytarabine - adverse effects | Stem Cell Transplantation | Melphalan - adverse effects | Antineoplastic Agents - adverse effects | Podophyllotoxin - administration & dosage | Adult | Carmustine - adverse effects | Survival Rate | Lymphoma, Large B-Cell, Diffuse - prevention & control | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Melphalan - administration & dosage | Antibodies, Monoclonal - administration & dosage | Aged | Carmustine - administration & dosage | Chemotherapy | Nuclear radiation | Stem cells | Etoposide | Clinical trials | Dosage and administration | Product development | Transplantation | Non-Hodgkin's lymphomas | Cancer | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2000, Volume 96, Issue 9, pp. 2934 - 2942
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 03/2018, Volume 36, Issue 7, pp. 697 - 697
Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine,... 
1ST-LINE TREATMENT | TOSITUMOMAB/IODINE I-131 TOSITUMOMAB | ONCOLOGY | COMPLETE RESPONSE | CLINICAL-TRIALS | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | LOW-GRADE | ACUTE MYELOID-LEUKEMIA | INDOLENT | CHEMOTHERAPY
Journal Article
EXPERT OPINION ON BIOLOGICAL THERAPY, ISSN 1471-2598, 04/2005, Volume 5, Issue 4, pp. 577 - 588
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.